✦ LIBER ✦

How do patients with neglect see a horizontal line?

✍ Scribed by Kaori Misonou; Sumio Ishiai; Keiko Seki; Yasumasa Koyama; Naomi Nakano

Publisher: Springer
Year: 2004
Tongue: English
Weight: 318 KB
Volume: 251
Category: Article
ISSN: 0340-5354
DOI: 10.1007/s00415-004-0404-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

General Surgery in Patients With a Bleed

General Surgery in Patients With a Bleeding Diathesis: How We Do It

✍ Kamal R. Aryal; D. Wiseman; Ajith K. Siriwardena; Paula H. B. Bolton-Maggs; Char 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 428 KB

Acalculia in a patient with severe langu

Acalculia in a patient with severe language disturbances: how do we test it?

✍ Elena Cecilia Rosca 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 189 KB

How I do it: Preoperative localization i

How I do it: Preoperative localization in patients with difficult re-explorations for hyperparathyroidism

✍ Haines, Gregory A.; Miller, Donald L.; Turton, David B.; Ghosh, Bimal C. 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 2 views

More than 90% of patients with primary hyperparathyroidism are cured by their first operation. In these patients, no preoperative localization procedures are nor-

Prognostic features and outcome in patie

Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens

✍ Luis Villela; Armando López-Guillermo; Silvia Montoto; Susana Rives; Francesc Bo 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

Mitomycin-C and capecitabine as third-li

Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study

✍ Do Hyoung Lim; Young Suk Park; Byeong-Bae Park; Sang Hoon Ji; Jeeyun Lee; Keon W 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 200 KB

Cost-effectiveness of epidermal growth f

Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung

✍ Gilberto de Lima Lopes Jr.; Joel E. Segel; Daniel S. W. Tan; Young K. Do; Tony M 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 870 KB

## Abstract ## BACKGROUND: Epidermal growth factor receptor (EGFR) testing and first‐line therapy with gefitinib for patients with activating mutations is quickly becoming the standard option for the treatment of advanced lung adenocarcinoma. Yet, to date, little is known about the cost‐effectiven